bafetinib experimental cancer drug developed nippon shinyaku licensed cytrx inhibitor lyn reached phase ii clinical trials imatinib first bcrabl tyrosinekinase inhibitor highly successful treatment chronic myelogenous leukemia previous effective treatment emerging resistance imatinib treatment alternative treatment highly sought bafetinib created attempt potent drug imatinib efficacy various point mutations bcrabl kinase fewer adverse effects narrower kinase spectra namely lyn search substance fit criteria mentioned crystal structure imatinib bound abl examined revealed hydrophobic pocket around phenyl ring adjacent piperazinylmethyl group imatinib attempts utilize pocket increase efficacy led addition various hydrophobic groups including single fluoro bromo chloro substituents finally trifluoromethyl group position found give best results approximately improvement imatinib addition hydrophobic group needed countered sustain solubility substance closer examination crystal structure imatinibkinase complex revealed close proximity pyridine ring imatinib suggesting little room larger group mind hydrophilic pyrimidine ring substituted pyridine found increase solubility leaving efficacy even slightly greater finally improve hydrogen bonding piperazine ring imatinib pyrrolidine azetidine derivatives introduced promising substance final modifications labeled fda granted orphan drug status treatment chronic myeloid due structural similarities imatinib bafetinib binding bcrabl also quite similar notable difference comes hydrophobic interaction trifluoromethyl group hydrophobic pocket created group also linked bafetinibs specificity lyn binding site almost identical bafetinib effective imatinib resistant mutations including dasatinib resistant mutations bafetinib also affinity bcrabl nilotinib less dasatinib targets bcrabl src family kinases lck lyn unrivalled specificity suggests probability fewer adverse bafetinib phase ii clinical trials treatment leukemia httpsenwikipediaorgwikibafetinib